Abstract This publication presents a systematic analysis of vitamin d deficiency and semaglutide connection. Evidence is drawn from randomized controlled trials, post-marketing surveillance databases, and real-world clinical outcomes data. Published by the WHIN Editorial Board for educational and research purposes.

Vitamin D Deficiency and Semaglutide Connection

Vitamin D Deficiency and Semaglutide Connection

People taking semaglutide (Ozempic/Wegovy) frequently ask how the medication affects their vitamin D (25-hydroxyvitamin D) readings. Here we evaluates available data on whether semaglutide influences serum 25(OH)D levels.


Clinical Evidence

What to Expect

Based on clinical trial data and patient monitoring data, semaglutide has been associated with changes in vitamin D (25-hydroxyvitamin D) through multiple mechanisms:

The pathways include:

  • Direct pharmacological effect: semaglutide acts directly upon cellular mechanisms that influence serum 25(OH)D levels
  • Secondary to weight reduction: Significant weight loss itself alters numerous blood test results — separating drug effect from weight-loss effect is challenging
  • Dietary changes: Reduced food intake affects nutrient absorption and could influence blood markers separately from pharmacological effects

Marker-by-Marker Analysis

Studies demonstrates that semaglutide produces positive shifts in:

  • Markers related to metabolic syndrome frequently normalize — this is one of the drug’s documented benefits
  • The magnitude of change is proportional to the amount of weight lost — more weight loss generally means more pronounced changes

What May Worsen or Change

Particular tests may change in noteworthy patterns:

  • Some values might initially worsen when starting the medication before improving
  • Dehydration from GI side effects may falsely affect concentration-dependent lab values
  • Fast body mass reduction mobilizes substances from fat tissue that may briefly elevate particular test results

When to Test

In line with clinical guidelines:

Baseline Testing

Prior to initiating semaglutide, your provider should order:

  • serum 25(OH)D levels — as a reference point
  • Complementary labs as clinically indicated based on your medical history

Ongoing Surveillance

StageRecommended Testing
BaselineFull panel
3 monthsTargeted repeat testing
6 monthsComplete recheck
AnnuallyFull reassessment
When neededTargeted testing

Red Flags

Alert your healthcare team promptly if:

  • Lab values go far outside normal ranges
  • You develop health changes that correspond to out-of-range values
  • Values continue trending in a concerning direction after dose changes

Practical Implications

Most lab changes occurring during semaglutide use are well-documented and within acceptable parameters when adequately surveilled.

What matters most is ongoing surveillance — beyond isolated lab draws but trending over time that reveal direction and magnitude.

Partner with your provider to create a surveillance protocol that is specific to your individual risk factors and drug and dose.

Suggested Citation

WHIN Research. (2026). Vitamin D Deficiency and Semaglutide Connection. World Health Innovation Network. Retrieved from https://worldhealthinnovationnetwork.com/vitamin-d-deficiency-semaglutide-connection/